MHDIs mentioned in this section, therefore, provide beneficial effects against tau hyperphosphorylation through the upregulation of p-Akt and PP2A expression and the downregulation of GSK-3β and CDK5 expression in the hippocampus in the early and late phases of AD in animal models (Table 3 and Figure 3). Here, PTPA is linked to Alzheimer disease.